Oligodendroglioma classification
Oligodendroglioma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Oligodendroglioma classification On the Web |
American Roentgen Ray Society Images of Oligodendroglioma classification |
Risk calculators and risk factors for Oligodendroglioma classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]Sujit Routray, M.D. [3]
Overview
Oligodendroglioma may be classified according to the WHO classification of the central nervous system tumors into five subtypes: oligodendroglioma (OII), anaplastic oligodendroglioma (OIII), oligoastrocytoma (OAII), anaplastic oligoastrocytoma (OAIII), and glioblastoma with oligodendroglioma component (GBMo).
Classification
- As of the 2016 edition of the WHO classification, gliomas are classified based not only on histopathologic appearance but also on well-established molecular parameters
- As of the 2016 update of the World Health Organization (WHO) classification of central nervous system tumors, oligodendroglial tumors are now more narrowly defined by molecular diagnostics to include only those diffuse gliomas harboring both a mutation in isocitrate dehydrogenase type 1 (IDH1) or type 2 (IDH2) and codeletion of chromosomes 1p and 19q.[1][2][3][4][5][6][7][8][9]
Tumor classification | Tumor grade | Defining* or characteristic molecular genetic features |
---|---|---|
Astrocytic tumors | ||
Diffuse astrocytoma, IDH-mutant | II | IDH1/2 mutation*, TP53 mutation, ATRX mutation |
Diffuse astrocytoma, IDH-wildtype | II | No IDH1/2 mutation |
Anaplastic astrocytoma, IDH-mutant | III | IDH1/2 mutation*, TP53 mutation, ATRX mutation |
Anaplastic astrocytoma, IDH-wildtype | III | No IDH1/2 mutation |
Glioblastoma, IDH-mutant | IV | IDH1/2 mutation*, TP53 mutation, ATRX mutation |
Glioblastoma, IDH-wildtype | IV | No IDH1/2 mutation, TERT promoter mutations |
Glioblastoma, NOS | IV | Genetic testing not done or inconclusive |
Midline diffuse glioma, H3 K27M-mutant | IV | H3 K27M mutation* |
Oligodendroglial tumors | ||
Oligodendroglioma, IDH-mutant and 1p/19q-codeleted | II | IDH1/2 mutation*, 1p/19q-codeletion*, no ATRX mutation, TERTpromoter mutations |
Oligodendroglioma, NOS | II | Genetic testing not done or inconclusive |
Oligoastrocytoma, NOS | II | Genetic testing not done or inconclusive |
Anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted | III | IDH1/2 mutation*, 1p/19q-codeletion*, no ATRX mutation, TERTpromoter mutations |
Anaplastic oligodendroglioma, NOS | III | Genetic testing not done or inconclusive |
Anaplastic oligoastrocytoma, NOS | III | Genetic testing not done or inconclusive |
IDH: isocitrate dehydrogenase; NOS: not otherwise specified
* Alterations that define the WHO classification entity are marked by an asterisk
Data from: WHO classification of tumours of the central nervous system, revised 4th ed, Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), IARC, Lyon 2016
- Oligodendroglioma may be classified according to the 2007 WHO classification of the central nervous system tumors into five subtypes:[10]
WHO classification of tumors of CNS | |||||||||||||||||||||||||||||||||||||||||||||
WHO grade II | WHO grade III | WHO grade IV | |||||||||||||||||||||||||||||||||||||||||||
Oligodendroglioma (OII) | |||||||||||||||||||||||||||||||||||||||||||||
Reference
- ↑ Perry A (2016). "WHO's arrived in 2016! An updated weather forecast for integrated brain tumor diagnosis". Brain Tumor Pathol. 33 (3): 157–60. doi:10.1007/s10014-016-0266-4. PMID 27295314.
- ↑ Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK; et al. (2016). "The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary". Acta Neuropathol. 131 (6): 803–20. doi:10.1007/s00401-016-1545-1. PMID 27157931.
- ↑ Perry A, Burton SS, Fuller GN, Robinson CA, Palmer CA, Resch L; et al. (2010). "Oligodendroglial neoplasms with ganglioglioma-like maturation: a diagnostic pitfall". Acta Neuropathol. 120 (2): 237–52. doi:10.1007/s00401-010-0695-9. PMC 2892612. PMID 20464403.
- ↑ Teo JG, Gultekin SH, Bilsky M, Gutin P, Rosenblum MK (1999). "A distinctive glioneuronal tumor of the adult cerebrum with neuropil-like (including "rosetted") islands: report of 4 cases". Am J Surg Pathol. 23 (5): 502–10. PMID 10328080.
- ↑ Rodriguez FJ, Scheithauer BW, Robbins PD, Burger PC, Hessler RB, Perry A; et al. (2007). "Ependymomas with neuronal differentiation: a morphologic and immunohistochemical spectrum". Acta Neuropathol. 113 (3): 313–24. doi:10.1007/s00401-006-0153-x. PMID 17061076.
- ↑ Brat DJ, Hirose Y, Cohen KJ, Feuerstein BG, Burger PC (2000). "Astroblastoma: clinicopathologic features and chromosomal abnormalities defined by comparative genomic hybridization". Brain Pathol. 10 (3): 342–52. PMID 10885653.
- ↑ Jouvet A, Fauchon F, Liberski P, Saint-Pierre G, Didier-Bazes M, Heitzmann A; et al. (2003). "Papillary tumor of the pineal region". Am J Surg Pathol. 27 (4): 505–12. PMID 12657936.
- ↑ Wang M, Tihan T, Rojiani AM, Bodhireddy SR, Prayson RA, Iacuone JJ; et al. (2005). "Monomorphous angiocentric glioma: a distinctive epileptogenic neoplasm with features of infiltrating astrocytoma and ependymoma". J Neuropathol Exp Neurol. 64 (10): 875–81. PMID 16215459.
- ↑ Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR; et al. (1998). "Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas". J Natl Cancer Inst. 90 (19): 1473–9. PMID 9776413.
- ↑ Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A; et al. (2007). "The 2007 WHO classification of tumours of the central nervous system". Acta Neuropathol. 114 (2): 97–109. doi:10.1007/s00401-007-0243-4. PMC 1929165. PMID 17618441.